-
Philippine museum brings deadly, lucrative galleon trade to life
-
Opening remarks Tuesday in Elon Musk versus OpenAI
-
New York restaurant's $40 half chicken fuels cost of dining debate
-
Trump shooting scare renews 'staged' conspiracy theory
-
LIV Golf postpones June event set for New Orleans: reports
-
Colombian peace accord failed to protect nature: ex-leader Santos
-
Nations have chance to break 'fossil fuel mindset': Mary Robinson
-
Colombia in mourning after deadliest attack in decades
-
Jury in place for Elon Musk's legal battle with OpenAI
-
Weinstein rape accuser gives emotional testimony at US retrial
-
Rybakina crashes out of Madrid Open, Sabalenka reaches quarters
-
Trump and team renew attacks on adversaries after gala shooting
-
Carrick hails Casemiro and Fernandes after vital Man Utd win
-
Felix, 40, says she plans comeback for LA Olympics
-
French FM says Iran must make 'major concessions' to end crisis
-
Trains collide near Jakarta, killing five, injuring dozens
-
Britain's King Charles meets Trump in bid to salvage ties
-
Accused media gala gunman charged with attempting to assassinate Trump
-
Man Utd beat Brentford to close on Champions League berth
-
Third suspect pleads guilty in US murder of Jam Master Jay
-
Milei bars media from presidential palace
-
California billionaire tax appears headed to the ballot
-
Trains collide near Jakarta, killing four, injuring dozens
-
Kompany hails Kane, 'ageing like fine wine' as Bayern face PSG in Champions League
-
UK's King Charles arrives in US to shore up Trump ties
-
Tuareg rebels in control of key Mali town
-
US Supreme Court hears Bayer bid to end Roundup weedkiller suits
-
Separate goals, common enemy for Mali's jihadists and separatists
-
Accused media gala shooter charged with attempted Trump assassination
-
UK's King Charles seeks to shore up Trump ties
-
Tourism plummets in US-blockaded Cuba
-
Taylor Swift files to trademark her voice amid AI clone boom
-
Trains collide outside Jakarta, killing four: officials
-
EU tells Google to open Android to AI rivals
-
Italian Calzona quits as Slovakia coach
-
21 killed in deadliest Colombia bombing in decades
-
Hazlewood, Kumar spark Delhi collapse as Bengaluru romp to victory
-
UN maritime agency rejects Hormuz tolls
-
Human Rights Watch warns of 'exclusion and fear' at World Cup
-
Tuareg rebels in control of key Mali town after offensive
-
Joshua signs deal to face Fury in all-British grudge match
-
Melania Trump slams Kimmel joke likening her to an 'expectant widow'
-
Carney launches $18 billion Canada sovereign wealth fund
-
Modric suffers fractured cheekbone, will go under the knife: AC Milan
-
'Looming' risk of nuclear arms race, UN proliferation meeting hears
-
Suspect due in court over shooting at Trump gala
-
Sabalenka downs Osaka to reach Madrid Open quarter-finals
-
'Nobody is better than us' says Luis Enrique as PSG prepare for Bayern
-
Hridoy, Shamim pull off record home chase for Bangladesh against NZ
-
Thrilling Kvaratskhelia hoping to drive PSG to another Champions League final
Lumira Ventures Announces Promotion of Suman Rao to Principal
Lumira Ventures, a leading North American life sciences investment firm dedicated to advancing healthcare innovation and enhancing patient outcomes, is pleased to announce the promotion of Suman Rao, Ph.D., to the role of Principal. This well-deserved promotion acknowledges her significant contributions to the firm's success and her steadfast commitment to fostering innovative healthcare solutions.
Dr. Rao joined Lumira Ventures in 2021 as an Associate and was promoted to Senior Associate in 2024, as she built out her skills and experience in all dimensions of the venture capital value chain. Her deep understanding of industry sectors like oncology and neuroscience coupled with her ability to foster strong relationships with entrepreneurs, co-investors, and industry stakeholders has made her a sought-after team member. Dr. Rao has been deeply involved with the firm's investments in Arclight Therapeutics, Congruence Therapeutics, and Damona Pharmaceuticals (as a board observer). Her contributions extend to being actively engaged in a number of the firm's strategic initiatives, including the Angelini Lumira Biosciences Fund and currently co-leading the Cancer Breakthrough Fund, a first-of-its-kind collaboration in Canada between a philanthropic organization (Terry Fox Foundation) and a VC firm with the goal to bring more capital to the mission of finding cures for cancers.
"We are delighted to elevate Suman to the role of Principal," said Peter van der Velden, Managing General Partner at Lumira Ventures. "Her growth at the firm and ability to take on more responsibility reflects our commitment to growing talent in-house and her dedication to developing the skills, expertise, and relationships that are the foundation of being a great VC."
"I am thrilled to be stepping into the role of Principal and grateful for the trust and support of my partners and colleagues," said Dr. Rao. "Together with an incredibly talented team, I look forward to supporting passionate entrepreneurs tackling some of medicine's biggest challenges today and building transformative companies."
Dr. Rao earned her Ph.D. in Experimental Medicine and her Bachelor's degree in Biochemistry from McGill University. Before joining Lumira Ventures, she completed a prestigious postdoctoral fellowship at the Dana-Farber Cancer Institute and Harvard Medical School. Dr. Rao also brings valuable experience from her time as a management consultant at L.E.K Consulting, where she provided strategic advice to biotech and pharma clients, further honing her expertise in the life sciences sector.
About Lumira Ventures
Lumira Ventures is a leading multi-stage life sciences investment firm operating across Toronto, Montréal, Vancouver, and Boston. As Canada's largest and most active dedicated life sciences venture capital investor, Lumira invests in first-in-class innovations in "secondary" geographies, partnering with mission-driven entrepreneurs to develop transformative therapeutics products and medical devices while generating strong financial returns and societal impact.
With a proven track record, Lumira Ventures has consistently delivered both financial success and transformative medical advancements. With portfolio companies having introduced over 50 biomedical innovations, improving the lives of over 1 billion patients worldwide and generating more than $70B in cumulative revenue.
For more information, please contact: [email protected]
www.lumiraventures.com
SOURCE: Lumira Ventures
L.Mason--AMWN